Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sherene Loi

Showing results (21-30 of 325) with videos related to

Pageof 33
Sort By:
Breast (Edinburgh, Scotland)|August 10, 2015
Molecular segmentation of luminal breast: Reality in 2015?Zhi Ling Teo, Sherene Loi
Med (New York, N.Y.)|May 19, 2022
Extended adjuvant aromatase inhibitor therapy: less is moreStephen J Luen, Sherene Loi
Current Treatment Options in Oncology|May 24, 2023
Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?Julia Dixon-Douglas, Sherene Loi
Critical Reviews in Oncology/Hematology|November 8, 2006
The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen responseSherene Loi, Martine Piccart, Christos Sotiriou
Current Opinion in Oncology|September 11, 2012
Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?Dimitrios Zardavas, Debora Fumagalli, Sherene Loi
Breast Cancer Research and Treatment|September 6, 2021
Seeing the forest and the tree: TILs and PD-L1 as immune biomarkersPeter Savas, Roberto Salgado, Sherene Loi
F1000Research|August 27, 2019
Triple-negative breast cancer: recent treatment advancesAlice R T Bergin, Sherene Loi
Breast Care (Basel, Switzerland)|August 2, 2013
Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?John Stagg, Fabrice Andre, Sherene Loi
Breast Cancer Research : BCR|September 6, 2014
PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical dataDimitrios Zardavas, Wayne A Phillips, Sherene Loi
Oncotarget|August 7, 2019
Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapyStephen L Luen, Roberto Salgado, Sherene Loi
Pageof 33

Showing results (21-30 of 325) with videos related to

Sort By:
Pageof 33
Breast (Edinburgh, Scotland)|August 10, 2015
Molecular segmentation of luminal breast: Reality in 2015?Zhi Ling Teo, Sherene Loi
Med (New York, N.Y.)|May 19, 2022
Extended adjuvant aromatase inhibitor therapy: less is moreStephen J Luen, Sherene Loi
Current Treatment Options in Oncology|May 24, 2023
Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?Julia Dixon-Douglas, Sherene Loi
Critical Reviews in Oncology/Hematology|November 8, 2006
The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen responseSherene Loi, Martine Piccart, Christos Sotiriou
Current Opinion in Oncology|September 11, 2012
Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?Dimitrios Zardavas, Debora Fumagalli, Sherene Loi
Breast Cancer Research and Treatment|September 6, 2021
Seeing the forest and the tree: TILs and PD-L1 as immune biomarkersPeter Savas, Roberto Salgado, Sherene Loi
F1000Research|August 27, 2019
Triple-negative breast cancer: recent treatment advancesAlice R T Bergin, Sherene Loi
Breast Care (Basel, Switzerland)|August 2, 2013
Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?John Stagg, Fabrice Andre, Sherene Loi
Breast Cancer Research : BCR|September 6, 2014
PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical dataDimitrios Zardavas, Wayne A Phillips, Sherene Loi
Oncotarget|August 7, 2019
Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapyStephen L Luen, Roberto Salgado, Sherene Loi
Pageof 33